Biotech

Clovis Oncology (NASDAQ: CLVS) today announced the submission of a regulatory application to the European Medicines Agency (EMA), as part of a type II variation seeking to expand the marketing authorization for Rubraca (rucaparib) to include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a …

Clovis Oncology (NASDAQ: CLVS) today announced the submission of a regulatory application to the European Medicines Agency (EMA), as part of a type II variation seeking to expand the marketing authorization for Rubraca (rucaparib) to include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy.

As quoted in the press release:

On May 29, 2018, Rubraca became the first PARP inhibitor licensed in the EU as a monotherapy treatment for women with recurrent ovarian cancer. It is currently indicated for adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The Rubraca Summary of Product Characteristics is available on the European Medicines Agency website.

Click here to read the full press release.

MARKETS

Markets
TSX18444.22+2.38
TSXV594.13+11.54
DOW28725.51-500.10
S&P 5003585.62-54.85
NASD10575.62-161.89
ASX6555.00+93.00

COMMODITIES

Commodities
Gold1660.90-3.67
Silver19.03+0.13
Copper3.39-0.03
Palladium2168.00-37.00
Platinum864.50-5.50
Oil79.74-1.49
Heating Oil3.23-0.07
Natural Gas6.83-0.05

DOWNLOAD FREE REPORTS

×